Evidence map›Paper›PMID 35734783›Full record

ReviewBioengineered2022

Prodigiosin: a promising biomolecule with many potential biomedical applications.

German A Islan, Boris Rodenak-Kladniew, Nehuen Noacco, Nelson Duran, Guillermo R Castro

Abstract readReview
In one paragraph

Review in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. A gut commensalVirulence · 2026
    Article
  2. Metacycloprodigiosin produced by a high-yieldOrganic & biomolecular chemistry · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. International journal of molecular sciences · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Promising Prodiginins Biological Activities.Chemistry & biodiversity · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

German A IslanDesarrollo en Fermentaciones Industriales (CINDEFI), Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP) -CONICET (CCT La Plata)Laboratorio de Nanobiomateriales, Centro de Investigación y , La Plata, Argentina.
Boris Rodenak-KladniewFacultad de Ciencias Médicas, Instituto de Investigaciones Bioquímicas de La Plata (INIBIOLP), CONICET-UNLP, CCT-La Plata, La Plata, Pcia de Bueos aires, Argentina.
Nehuen NoaccoDesarrollo en Fermentaciones Industriales (CINDEFI), Facultad de Ciencias Exactas, Universidad Nacional de La Plata (UNLP) -CONICET (CCT La Plata)Laboratorio de Nanobiomateriales, Centro de Investigación y , La Plata, Argentina.
Nelson DuranLaboratory of Urogenital Carcinogenesis and Immunotherapy, Biological Institute, Department of Structural and Functional Biology, University of Campinas, Campinas, Brazil.
Guillermo R CastroLaboratory of Urogenital Carcinogenesis and Immunotherapy, Biological Institute, Department of Structural and Functional Biology, University of Campinas, Campinas, Brazil.ORCID 0000-0002-6187-7805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pigments are among the most fascinating molecules found in nature and used by human civilizations since the prehistoric ages. Although most of the bio-dyes reported in the literature were discovered around the eighties, the necessity to explore novel compounds for new biological applications has made them resurface as potential alternatives. Prodigiosin (PG) is an alkaloid red bio-dye produced by diverse microorganisms and composed of a linear tripyrrole chemical structure. PG emerges as a really interesting tool since it shows a wide spectrum of biological activities, such as antibacterial, antifungal, algicidal, anti-Chagas, anti-amoebic, antimalarial, anticancer, antiparasitic, antiviral, and/or immunosuppressive. However, PG vehiculation into different delivery systems has been proposed since possesses low bioavailability because of its high hydrophobic character (XLogP3-AA = 4.5). In the present review, the general aspects of the PG correlated with synthesis, production process, and biological activities are reported. Besides, some of the most relevant PG delivery systems described in the literature, as well as novel unexplored applications to potentiate its biological activity in biomedical applications, are proposed.

Indexed as

Antineoplastic AgentsProdigiosinAnti-Bacterial AgentsAntifungal AgentsHumansSerratia marcescensAnti-Bacterial AgentsAntifungal AgentsAntineoplastic AgentsProdigiosinanticancerantifungalantimicrobialProdigiosinprodigiosin biological activitiesprodigiosin productionserratia marcescens

Identifiers

PMID35734783
PMCPMC9342244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.